Therapeutic application of thalidomide in multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 583-587

  Kyle, R A ^a   Rajkumar, S V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; M PROTEIN; PARAPROTEIN; THALIDOMIDE; VINCRISTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONSTIPATION; DOSE CALCULATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTHYROIDISM; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; THROMBOSIS; TUMOR VASCULARIZATION;

EID: 0035214179     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90028-4     Document Type: Article

References (22)

1. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
2. Antitumor activity of thalidomide in refractory multiple myeloma
3. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion
4. Pharmacology of thalidomide
5. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
6. Thalidomide-induced hypercoagulability in multiple myeloma (MM)
7. Thalidomide in the treatment of relapse multiple myeloma
8. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies
9. Thalidomide with dexamethasone for resistant multiple myeloma
10. Thalidomide in patients with advanced myeloma: Survival prognostic factors
11. Non-myelosuppressive therapy with BLT-D (Biaxin, low dose thalidomide and dexamethasone) is highly active in Waldenström's macroglobulinemia and myeloma
12. Thalidomide in multiple myeloma
13. Thalidomide plus dexamethasone (THAL/DEX) and thalidomide alone (THAL) as first-line therapy for newly-diagnosed myeloma (MM)
14. Thalidomide alone or with dexamethasone for multiple myeloma
15. Efficacy of low-dose thalidomide (T) in multiple myeloma
16. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
17. Therapy with thalidomide in refractory multiple myeloma - The revival of an old drug
18. Clinical and biological activity of thalidomide (THAL) in multiple myeloma (MM)
19. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters
20. Thalidomide is effective in the treatment of recurrent refractory multiple myeloma (MM)
21. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients
22. Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant